---
schema_version: "secwatch.filing_event.v1"
accession: "0001549084-23-000057"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:26:17.371047+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics Q2 2023 record revenue $4.7M, up 36% YoY; net loss $0.31/share

## Summary
- Revenue $4.7M (+36% YoY); gross profit $2.3M (48% margin) vs $1.6M (47%) in Q2 2022.
- Net loss $4.2M ($0.31 diluted EPS) vs $3.0M ($0.23) a year ago, driven by HMC acquisition costs.
- Booked 44 EksoHealth devices in Q2; cash $13.3M at June 30, 2023 versus $20.5M at Dec 31, 2022.
- Sales & marketing $2.3M, R&D $1.4M, G&A $2.8M; all up YoY due to HMC integration and severance.
- Six-month 2023 revenue $8.8M (+46% YoY); net loss $8.6M compared to $7.6M in H1 2022.

## SEC filing metadata
- accession: 0001549084-23-000057
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000057/0001549084-23-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000057/ekso-20230727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549084-23-000057
- JSON: https://secwatch.observer/filing/0001549084-23-000057.json
- Plain text: https://secwatch.observer/filing/0001549084-23-000057.txt

## Key facts
- Earnings Releases
  EKSO BIONICS HOLDINGS, INC. reported the quarter ended June 30, 2023 results: revenue $4.7 million, net income $4.2 million, EPS $0.31 per basic and diluted share.
  - Period: the quarter ended June 30, 2023
  - Revenue: $4.7 million
  - Net income: $4.2 million
  - EPS: $0.31 per basic and diluted share
  - Result: reported results
  source text: Revenue was $4.7 million for the quarter ended June 30, 2023, an increase of 36%, compared to $3.5 million for the same period in 2022. The Company booked a total of 44 EksoHealth devices in the second quarter of 2023. Gross profit for the quarter ended June 30, 2023 was $2.3 million, an increase of 37% from the same period in 2022, representing a gross margin of approximately 48% in the second quarter of 2023, compared to a gross margin of 47% for the same period in 2022. The increase in gross margin was primarily due to lower device costs. Sales and marketing expenses for the quarter ended June 30, 2023 were $2.3 million, compared to $1.8 million for the same period of 2022. The increase was primarily due to higher compensation costs associated with the acquisition of the Human Motion Control (“HMC”) business unit, severance expense and an increase in marketing activities. Research and development expenses for the quarter ended June 30, 2023 were $1.4 million, compared to $0.9 millio
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000057/0001549084-23-000057-index.htm
- Earnings Releases
  EKSO BIONICS HOLDINGS, INC. reported the six months ended June 30, 2023 results: revenue $8.8 million, net income $8.6 million, EPS $0.64 per basic and diluted share.
  - Period: the six months ended June 30, 2023
  - Revenue: $8.8 million
  - Net income: $8.6 million
  - EPS: $0.64 per basic and diluted share
  - Result: reported results
  source text: Revenue was $8.8 million for the six months ended June 30, 2023, an increase of 46%, compared to $6.0 million for the same period in 2022. The Company booked a total of 67 EksoHealth devices in the first half of 2023. Gross profit for the six months ended June 30, 2023 was $4.3 million, representing a gross margin of approximately 48%, compared to gross profit of $2.9 million for the same period in 2022, representing a gross margin of 47%. The overall increase in gross margin was primarily due to lower device costs. Sales and marketing expenses for the six months ended June 30, 2023 were $4.4 million, compared to $3.5 million the same period in 2022. The increase was primarily due to higher compensation costs associated with the acquisition of HMC, an increase in marketing activities, and severance expense. Research and development expenses for the six months ended June 30, 2023 were $2.6 million, compared to $1.8 million for the same period in 2022. The increase was primarily due to h
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000057/0001549084-23-000057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.